LYC-53772 and LYC-54143, as potent RORγ synthetic agonists, can boost the differentiation of Th17 cells, block immunosuppression driven by Tregs and significantly elevate the level of secreted cytokines, including IL-17A, IL-17F, and GM-CSF, and IL-22, such that an anti-tumor activity is implicated [116]. The gene discussed is IL17A; the disease is neoplasm.